Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572501 | 1.00 | HTR7 (0.53) | HTR7RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL23092046 | 0.84 | KCNN4 (0.43) | HTR7RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL3185351 | 0.84 | CA12 (0.48) | MAPTL3MBTL1CYP1A2LMNASMN1; SMN2 | |
| SCHEMBL30741241 | 0.84 | CA12 (0.48) | MAPTL3MBTL1CYP1A2LMNASMN1; SMN2 | |
| SCHEMBL30741239 | 0.84 | CA12 (0.48) | MAPTL3MBTL1CYP1A2LMNASMN1; SMN2 | |
| SCHEMBL9082172 | 0.83 | PTPN1 (0.39) | HTR7RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL31681465 | 0.83 | MAPT (0.50) | HTR7RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL17919290 | 0.82 | PTPN1 (0.45) | HTR7RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL6564781 | 0.82 | PTPN1 (0.41) | HTR7RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL1134362 | 0.81 | TAAR1 (0.44) | HTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271300-A | Lactam compound, and preparation method and application thereof | 广州市联瑞制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024046342-A1 | BENZO BICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州市联瑞制药有限公司 | 2024-03-07 | — | — | WO | disclosed |
| EP-4329765-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117203194-A | Novel compounds useful as STING agonists and uses thereof | 北京加科思新药研发有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | NOVIRA THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| WO-2022231927-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-4051672-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114650988-A | Fluorinated quinoline and quinoxaline derivatives as inhibitors of dihydroorotate dehydrogenase (DHODH) for the treatment of cancer, autoimmune and inflammatory diseases | 詹森生物科技公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2022087375-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5747540-A | ENZYME INHIBITORS HYDROXY INDOLEAMIDES, COUMARIN AMIDES AND ISOTHIOCOUMARIN AMIDES | MERCK & CO., INC. (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| EP-0391652-B1 | Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | SQUIBB & SONS INC (US) | 1995-03-15 | — | — | EP | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5126370-A | Anti-thrombotic heterocyclic amido prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1992-06-30 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0391652-A1 | Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0002097-A1 | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | HTR7 3519/4885RAB9A 642/4885MAPT 3192/4885 |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | DHODH, NQO2, DPYD | HTR7 3406/4885RAB9A 519/4885MAPT 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.